文献速递心脑血管急症

急性缺血性卒中应用替奈普酶或阿替普酶后24小时内显著不良事件发生率:多中心、单企业、回顾性研究

Incidence of significant adverse events within 24 h following administration of tenecteplase or alteplase for treatment of acute ischemic stroke: A multi-center, single-enterprise, retrospective study.
PubMed 文献 · Am J Emerg Med · 2025-06-14
一句话结论多中心回顾性研究显示,疑似急性缺血性卒中患者使用替奈普酶与阿替普酶后24小时内复合安全终点无统计学差异。

该研究为克利夫兰诊所医疗系统(CCHS)俄亥俄州和佛罗里达州机构的多中心、单企业、回顾性研究,纳入疑似急性缺血性卒中患者,比较阿替普酶(2020年1月1日至2022年1月10日)与替奈普酶(2022年2月1日至2023年9月20日)的安全性和有效性。共863例患者,476例接受阿替普酶,387例接受替奈普酶。主要复合终点(24小时颅内出血转化、血管性水肿和/或非颅内出血关键部位出血,以及院内全因死亡)在两组间无统计学差异。总体115例(13%)发生主要安全复合终点(95%CI=0.2[-4.4至4.8]),64例(7%)发生任何颅内出血,其中42例(5%)为症状性。结论认为替奈普酶与阿替普酶在CCHS佛罗里达州和俄亥俄州治疗的AIS患者中未观察到安全性风险差异。

要点

  • 863例疑似AIS患者中,476例接受阿替普酶、387例接受替奈普酶,主要安全复合终点无统计学差异(95%CI=0.2[-4.4至4.8])。
  • 总体任何颅内出血64例(7%),其中症状性42例(5%);阿替普酶组症状性颅内出血26例(5%),替奈普酶组16例(4%)(95%CI=-1.3[-4.2至1.5])。
  • 颅内出血转化阿替普酶组37例(8%),替奈普酶组27例(7%)(95%CI=-0.8[-4.3至2.7])。
  • 总体115例(13%)发生主要安全复合终点(24小时颅内出血转化、血管性水肿和/或非颅内出血关键部位出血,以及院内全因死亡)。

适用人群与场景

  • 在CCHS俄亥俄州或佛罗里达州机构因疑似急性缺血性卒中接受阿替普酶(2020年1月1日至2022年1月10日)或替奈普酶(2022年2月1日至2023年9月20日)治疗的患者。

研究设计与关键结果

  • 研究类型:多中心、单企业、回顾性研究;样本量863例(阿替普酶476例,替奈普酶387例);人群:CCHS俄亥俄州和佛罗里达州机构疑似AIS患者;干预:阿替普酶 vs 替奈普酶。
  • 主要复合终点(24小时颅内出血转化、血管性水肿和/或非颅内出血关键部位出血,以及院内全因死亡):115例(13%)发生,95%CI=0.2[-4.4至4.8],两组无统计学差异。
  • 任何颅内出血:64例(7%);症状性颅内出血:42例(5%)。
  • 颅内出血转化:阿替普酶组37例(8%) vs 替奈普酶组27例(7%),95%CI=-0.8[-4.3至2.7]。
  • 症状性颅内出血:阿替普酶组26例(5%) vs 替奈普酶组16例(4%),95%CI=-1.3[-4.2至1.5]。

证据类型、等级与局限

  • 证据类型:多中心、单企业、回顾性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论:在CCHS佛罗里达州和俄亥俄州接受AIS治疗的患者中,替奈普酶与阿替普酶之间未观察到安全性风险差异;主要复合终点无统计学差异。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: This study aims to evaluate differences in the safety profile between alteplase or tenecteplase for suspected acute ischemic stroke (AIS) at Cleveland Clinic Health System (CCHS) facilities in Ohio and Florida.

METHODS: This was a multi-center, single-enterprise, retrospective review of patients that received alteplase (January 1, 2020 - January 10, 2022) or tenecteplase (February 1, 2022 - September 20, 2023) for suspected AIS at CCHS Ohio or Florida. The composite primary outcome consisted of conversion to intracranial hemorrhage (ICH), angioedema, and/or non-ICH critical site bleeding at 24 h post-treatment, and in-hospital all-cause mortality. Secondary outcomes include incidence of symptomatic ICH, any ICH, angioedema, or critical site bleed within 24 h, and in-hospital all-cause mortality.

RESULTS: A total of 863 patients were identified with 476 receiving alteplase and 387 receiving tenecteplase. Total, 115 total patients (13 %) experienced the primary safety composite outcome (95 % CI = 0.2 [-4.4 to 4.8]), and 64 patients (7 %) experienced any ICH with 42 (5 %) being symptomatic. Of total ICH transformations, 37 (8 %) received alteplase and 27 (7 %) received tenecteplase (95 % CI = -0.8 [-4.3 to 2.7]; however, symptomatic ICH included 26 patients (5 %) treated with alteplase and 16 (4 %) with tenecteplase (95 % CI = -1.3 [-4.2 to 1.5]).

CONCLUSION: No statistical difference was observed in the primary composite outcome when treated with tenecteplase and alteplase for AIS treatment. There was no observed safety risk between tenecteplase and alteplase in patients treated for AIS at CCHS in Florida and Ohio.

DISCLOSURE: The individuals involved do not have anything to disclose concerning potential or actual financial or personal relationships with commercial entities (or their competitors) that may be referenced in this study.

MESH TERMS: Tissue plasminogen activator, tenecteplase, ischemic stroke, intracranial hemorrhage, retrospective studies.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Greiner SM, Marrison KE, Rigelsky FS, et al. Incidence of significant adverse events within 24 h following administration of tenecteplase or alteplase for treatment of acute ischemic stroke: A multi-center, single-enterprise, retrospective study. Am J Emerg Med. 2025. PMID: 40517709. doi:10.1016/j.ajem.2025.06.021

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。